Byrne Asset Management’s Autolus Therapeutics AUTL Stock Holding History

Byrne Asset Management’s Portfolio AUTL Stock Details AUTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$185	Hold	100	–	–	﹤0.01%	608
2026 Q2	$160	Hold	100	–	–	﹤0.01%	576
2026 Q1	$138	Hold	100	–	–	﹤0.01%	550
2025 Q4	$199	Sell	100 -125	-56%	-$192	﹤0.01%	544
2025 Q3	$367	Hold	225	–	–	﹤0.01%	548
2025 Q2	$513	Sell	225 -25	-10%	-$41	﹤0.01%	531
2025 Q1	$388	Hold	250	–	–	﹤0.01%	547
2024 Q4	$588	Sell	250 -1,150	-82%	-$3.89K	﹤0.01%	525
2024 Q3	$5.08K	Sell	1,400 -100	-7%	-$399	﹤0.01%	454
2024 Q2	$5K	Sell	1,500 -300	-17%	-$1.29K	﹤0.01%	442
2024 Q1	$11.5K	Sell	1,800 -900	-33%	-$5.61K	0.01%	349
2023 Q4	$17.9K	Buy	+2,700	New	+$10.3K	0.01%	304

Other funds holding AUTL

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Byrne Asset Management's AUTL Position: Q3 2026 in Review

Byrne Asset Management held its Autolus Therapeutics (AUTL) position steady in Q3 2026 at 100 shares worth $185. The position accounts for ﹤0.01% of the portfolio, ranked #608.

Byrne Asset Management first reported a position in AUTL in Q4 2023 and has held it in 12 quarters since. The position peaked at $17.9K in Q4 2023. 2 funds tracked by Wall St. Rank hold AUTL as of Q3 2026.

Byrne Asset Management held 100 shares of Autolus Therapeutics worth $185 as of Q3 2026.
Byrne Asset Management left its Autolus Therapeutics share count unchanged in Q3 2026.
Autolus Therapeutics made up ﹤0.01% of Byrne Asset Management's portfolio in Q3 2026, its #608 holding.
Byrne Asset Management first reported a position in Autolus Therapeutics in Q4 2023 and has held it in 12 quarters since.
Byrne Asset Management's Autolus Therapeutics position peaked at $17.9K in Q4 2023.
2 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q3 2026.

Based on Byrne Asset Management's 13F filing for Q3 2026, filed 6 Oct 2026.